BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 24343743)

  • 1. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
    Gao FF; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression.
    Li Z; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2015 Mar; 143(3):451-8. PubMed ID: 25696805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.
    Horii R; Matsuura M; Iwase T; Ito Y; Akiyama F
    Breast Cancer; 2014 Sep; 21(5):598-604. PubMed ID: 23307494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
    Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
    Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.
    Vranic S; Teruya B; Repertinger S; Ulmer P; Hagenkord J; Gatalica Z
    Cancer; 2011 Jan; 117(1):48-53. PubMed ID: 20803611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE; Marotti JD; Memoli VA; Wells WA; Tafe LJ
    Am J Clin Pathol; 2015 Aug; 144(2):247-52. PubMed ID: 26185309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
    Pu X; Shi J; Li Z; Feng A; Ye Q
    Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
    Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
    Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong.
    Tang SM; Soong IS; Luk MY; Suen DT; Hioe F; Man EP; Tsun OK; Khoo US
    Hong Kong Med J; 2016 Apr; 22(2):144-51. PubMed ID: 26823385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
    Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
    Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.